Therapy of murine mammary carcinoma metastasis with interferon γ and MHC gene-transduced tumour cells

British Journal of Cancer

Volumn 74, Issue 10, 1996, Pages 1564-1569

  Nanni, P ^a,e   De Giovanni, C ^a   Landuzzi, L ^a,b   Nicoletti, G ^a,b   Frabetti, F ^a   Rossi, I ^a   Cavallo, F ^c   Giovarelli, M ^c   Forni, G ^c,d   Lollini, P L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b IST   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Ctro CNR Immunogenetica Oncol S   (Italy)

^e Istituto di Cancerologia   (Italy)

Author keywords

Gene therapy; Interferon gamma; Major histocompatibility complex

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CARCINOGENESIS; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; IMMUNOLOGICAL MEMORY; INFLAMMATION; LUNG METASTASIS; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 10544251067     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.590     Document Type: Article

References (26)

1. ALLIONE A, CONSALVO M, NANNI P, LOLLINI P-L, CAVALLO F, GIOVARELLI M, GULINO A, COLOMBO MP, DELLABONA P, HOCK H, BLANKENSTEIN T, ROSENTHAL FM, GANSBACHER B, MUSSO T, GUSELLA L, FORNI M AND FORNI G. (1994). Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with IL2, IL4, IL6, IL7, IL10, TNF-alpha, GM-CSF and IFN-gamma gene or admixed with conventional adjuvants. Cancer Res., 54, 6022-6026.
2. CHEN PW AND ANANTHASWAMY HN. (1993). Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J. Immunol., 151, 244-255.
3. COLOMBO MP AND FORNI G. (1994). Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today, 15, 48-51.
4. COLOMBO MP, MODESTI A, PARMIANI G AND FORNI G. (1992). Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross talk. Cancer Res., 52, 4853-4857.
5. CONNOR J, BANNERJI R, SAITO S, HESTON W, FAIR W AND GILBOA E. (1993). Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J. Exp. Med., 177, 1127-1134.
6. DE GIOVANNI C, LOLLINI P-L, DEL RE B, NICOLETTI G, PRODI G, SCOTLAND IK AND NANNI P. (1988). Heterogeneity and clonal interactions in the TS/A murine mammary adenocarcinoma. In Cancer Metastasis - Biological and Biochemical Mechanisms and Clinical Aspects. Prodi G, Liotta LA, Lollini P-L, Garbisa S, Gorini S, Hellmann K (eds). pp. 5-14. Plenum Publishing: New York.
7. DE GIOVANNI C, NICOLETTI G, SENSI M, SANTONI A, PALMIERI G, LANDUZZI L, NANNI P AND LOLLINI P-L. (1994). H-2Kb and H-2Db gene transfections in B16 melanoma differently affect non-immunological properties relevant to the metastatic process. Involvement of integrin molecules. Int. J. Cancer, 59, 269-274.
8. DEABATE O, DI PIERRO F, DAMIA G, D'INCALCI M AND FORNI G. (1992). Synergistic therapeutical effect of peritumoral IL-1 and IL-4 and systemic cisplatinum administration in mice bearing tumors of progressive size. J. Immunol. Res., 4, 176-180.
9. DRANOFF G, JAFFEE E, LAZENBY A, GOLUMBEK P, LEVITSKY H, BROSE K, JACKSON V, HAMADA H, PARDOLL D AND MULLIGAN RC. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA, 90, 3559-3543.
10. ESUMI N, HUNT B, ITAYA T AND FROST P. (1991). Reduced tumorigenicity of tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. Cancer Res., 51, 1185-1189.
11. FRANCO JL, KOMSCHLIES KL, GRUYS ME, BACK TC, FENTON RG AND WILTROUT RH. (1994). Immunogenicity of murine renal cancer cells expressing various cytokine genes. In Cytokine Induced Tumor Immunogenicity. Forni G, Foa' R, Santoni A, Frati L (eds). pp. 175-187. Academic Press: New York.
12. GANSBACHER B, BANNERJI R, DANIELS B, ZIER K, CRONI K AND GILBOA E. (1990). Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res., 50, 7820-7825.
13. HOCK H, DORSCH M, KUNZENDORF U, QIN Z, DIAMANTSTEIN T AND BLANKENSTEIN T. (1993). Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon-gamma. Proc. Natl Acad. Sci. USA, 90, 2774-2778.
14. KELLY SA, GSCHMEISSNER S, EAST N AND BALKWILL FR. (1991). Enhancement of metastatic potential by gamma-interferon. Cancer Res., 51, 4020-4027.
15. LOLLINI P-L, BOSCO MC, CAVALLO F, DE GIOVANNI C, GIOVARELLI M, LANDUZZI L, MUSIANI P, MODESTI A, NICOLETTI G, PALMIERI G, SANTONI A, YOUNG HA, FORNI G AND NANNI P. (1993). Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int. J. Cancer, 55, 320-329.
16. LOLLINI P-L, DE GIOVANNI C, LANDUZZI L, NICOLETTI G, FRABETTI F, CAVALLO F, GIOVARELLI M, FORNI G, MODICA A, MODESTI A, MUSIANI P AND NANNI P. (1995). Transduction of genes coding for a histocompatibility (MHC) antigen and for its physiological inducer gamma-interferon in the same cell. Efficient MHC expression and inhibition of tumor and metastasis growth. Hum. Gene Ther., 6, 743-752.
17. MIZUNO M, YOSHIDA J, TAKAOKA T AND SUGITA K. (1994). Liposomal transfection of human gamma-interferon gene into human glioma cells and adoptive immunotherapy using lymphokine-activated killer cells. J. Neurosurg., 80, 510-514.
18. MUSIANI P, MODESTI A, BRUNETTI M, MODICA A, GULINO A, BOSCO MC, COLOMBO M, NANNI P, CAVALLO F, PERICLE F, GIOVARELLI M, CAVALLO R AND FORNI G. (1994). The nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with IL-2, IL-4 or IFN-gamma gene. Natural Immunity, 13, 93-101.
19. MUSIANI P, ALLIONE A, MODICA A, LOLLINI P-L, GIOVARELLI M, CAVALLO F, BELARDELLI F, FORNI G AND MODESTI A (1996). Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab. Invest., 74, 146-157.
20. OSTRAND-ROSENBERG S, ROBY C, CLEMENTS VK AND COLE GA. (1991). Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes. Int. J. Cancer. Suppl. 6, 61-68.
21. PORGADOR A, BANNERJI R, WATANABE Y, FELDMAN M, GILBOA E AND EISENBACH L. (1993). Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells. J. Immunol., 150, 1458-1470.
22. - T cells against the wild-type tumor: correlation with antigen presentation capability. J. Exp. Med., 175, 1423-1431.
23. TANAKA K, HAYASHI H, HAMADA C, KHOURY G AND JAY G. (1986). Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc. Natl Acad. Sci. USA, 83, 8723-8727.
24. TERAMURA Y, WATANABE Y, KAN N, MASUDA T AND KURIBAYASHI K. (1993). Interferon-gamma-producing tumor induces host tumor-specific T cell responses. Jpn. J. Cancer Res., 84, 689-696.
25. VIEWEG J, ROSENTHAL FM, BANNERJI R, HESTON WDW, FAIR WR, GANSBACHER B AND GILBOA E. (1994). Immunotherapy of prostate cancer in the dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res., 54, 1760-1765.
26. WATANABE Y, KURIBAYASHI K, MIYATAKE S, NISHIHARA K, NAKAYAMA E, TANIYAMA T AND SKATA T. (1989). Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl Acad. Sci. USA, 86, 9456-9460.